{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T05:19:03Z","timestamp":1788153543203,"version":"build-2803163510"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"\n Background<\/jats:title>\n Tegafur\u2013uracil (UFT) combined with radiotherapy is a treatment option for advanced pancreatic cancer. The purpose of this study was to evaluate the overall efficacy and safety of this combination therapy and explore potential factors associated with treatment outcomes.<\/jats:p>\n <\/jats:sec>\n \n Method<\/jats:title>\n The meta-analysis was in line with the PRISMA 2020 and MOOSE guidelines. Web of Science, PubMed, Scopus and Embase databases were searched for eligible studies. The outcomes variables were objective response rate (ORR) and adverse drug reaction (ADR). Pooled proportions were synthesized using meta-analysis method with a random-effect model. Influential publication was determined by performing a sensitivity analysis. In addition, the potential sources of heterogeneity were examined using subgroup analyses. Publication bias was assessed using a funnel plot, Begg\u2019s and Egger\u2019s tests.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n The 7 observational studies, included for the SRMA, were conducted between 2004 and 2016, involving secondary data of 237 patients who underwent UFT combined with radiotherapy. We found that the pooled ORR of UFT combined with radiotherapy was 38% (95% CI: 13% to 67%,\n P<\/jats:italic>\n \u00a0&lt;\u00a00.001), with high heterogeneity (I\n 2<\/jats:sup>\n \u00a0=\u00a094.25%,\n P<\/jats:italic>\n \u00a0&lt;\u00a00.001). The pooled ADR was 21% (95% CI: 10% to 34%,\n P<\/jats:italic>\n \u00a0&lt;\u00a00.001), with a high heterogeneity (I\n 2<\/jats:sup>\n \u00a0=\u00a076.25%,\n P<\/jats:italic>\n \u00a0&lt;\u00a00.001). Subgroup analyses revealed that patient age and UFT dosage were critical factors influencing outcomes. Specifically, compared with other doses, UFT (250 mg\/m2\/day) had a higher ORR (69%, 95% CI: 56% to 81%) and a lower ADR (6%, 95% CI: 1% to 14%).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n UFT combined with radiotherapy is an effective and tolerable treatment strategy for patients with advanced pancreatic cancer, with a pooled ORR of 38% and an ADR of 21%. Age of the patients and drug dosage were significant determinants of treatment outcomes. However, further research is needed to confirm these findings in large-scale randomized controlled trials.<\/jats:p>\n <\/jats:sec>\n \n Systematic Review Registration<\/jats:title>\n \n https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD420261377332<\/jats:ext-link>\n , identifier, CRD420261377332.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fonc.2026.1915790","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T04:29:47Z","timestamp":1788150587000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of UFT combined with radiotherapy in advanced pancreatic cancer: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Xiaoyun","family":"Shang","sequence":"first","affiliation":[{"name":"First Department of Hepatobiliary Surgery, The Fourth Affiliated Hospital of Dali University.","place":["Chuxiong, Yunnan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobo","family":"Wang","sequence":"additional","affiliation":[{"name":"First Department of Hepatobiliary Surgery, The Fourth Affiliated Hospital of Dali University.","place":["Chuxiong, Yunnan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawei","family":"Cen","sequence":"additional","affiliation":[{"name":"First Department of Hepatobiliary Surgery, The Fourth Affiliated Hospital of Dali University.","place":["Chuxiong, Yunnan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Yang","sequence":"additional","affiliation":[{"name":"First Department of Hepatobiliary Surgery, The Fourth Affiliated Hospital of Dali University.","place":["Chuxiong, Yunnan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juntao","family":"Li","sequence":"additional","affiliation":[{"name":"First Department of Hepatobiliary Surgery, The Fourth Affiliated Hospital of Dali University.","place":["Chuxiong, Yunnan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhao","sequence":"additional","affiliation":[{"name":"First Department of Hepatobiliary Surgery, The Fourth Affiliated Hospital of Dali University.","place":["Chuxiong, Yunnan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/j.annonc.2023.08.009","article-title":"Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Conroy","year":"2023","journal-title":"Ann Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41431-023-01301-3","article-title":"Abdominal obesity is a more important causal risk factor for pancreatic cancer than overall obesity","volume":"31","author":"Maina","year":"2023","journal-title":"Eur J Hum Genet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(26)00054-9","article-title":"AI-assisted screening for pancreatic cancer - Authors' reply","volume":"27","author":"Alves","year":"2026","journal-title":"Lancet Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00298","article-title":"The multicenter cancer of pancreas screening study: impact on stage and survival","volume":"40","author":"Dbouk","year":"2022","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2021-326311","article-title":"Pancreatic cancer: an increasing global public health concern","volume":"71","author":"Cabasag","year":"2022","journal-title":"Gut"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1404198","article-title":"Pancreatic adenocarcinoma","volume":"371","author":"Ryan","year":"2014","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.5306\/wjco.v16.i6.105849","article-title":"Advances in neoadjuvant therapy for pancreatic cancer: Current trends and future directions","volume":"16","author":"Wu","year":"2025","journal-title":"World J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3322\/caac.70035","article-title":"Advances in pancreatic cancer early diagnosis, prevention, and treatment: The past, the present, and the future","volume":"76","author":"Mannucci","year":"2026","journal-title":"CA Cancer J Clin"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00436","article-title":"PASS-01: randomized phase II trial of modified FOLFIRINOX versus gemcitabine\/nab-paclitaxel and molecular correlatives for previously untreated metastatic pancreatic cancer","volume":"43","author":"Knox","year":"2025","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13045-024-01561-6","article-title":"Current and future immunotherapeutic approaches in pancreatic cancer treatment","volume":"17","author":"Farhangnia","year":"2024","journal-title":"J Hematol Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00511-4","article-title":"Comparison of first-line chemotherapy regimens in unresectable locally advanced or metastatic pancreatic cancer: a systematic review and Bayesian network meta-analysis","volume":"25","author":"Mastrantoni","year":"2024","journal-title":"Lancet Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.4324","article-title":"Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial","volume":"315","author":"Hammel","year":"2016","journal-title":"Jama"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/bjsopen\/zrae087","article-title":"Neoadjuvant therapy versus upfront surgery in resectable pancreatic cancer: reconstructed patient-level meta-analysis of randomized clinical trials","volume":"8","author":"Aliseda","year":"2024","journal-title":"Bjs Open"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02274","article-title":"Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the dutch randomized phase III PREOPANC trial","volume":"38","author":"Versteijne","year":"2020","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s00595-007-3578-5","article-title":"UFT (tegafur and uracil) as postoperative adjuvant chemotherapy for solid tumors (carcinoma of the lung, stomach, colon\/rectum, and breast): clinical evidence, mechanism of action, and future direction","volume":"37","author":"Tanaka","year":"2007","journal-title":"Surg Today"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2021.0017","article-title":"Pancreatic adenocarcinoma, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Tempero","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032295","article-title":"A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer","volume":"350","author":"Neoptolemos","year":"2004","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003583","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"18","author":"Page","year":"2021","journal-title":"PloS Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group","volume":"283","author":"Stroup","year":"2000","journal-title":"Jama"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/jebm.12427","article-title":"The ROBINS-I and the NOS had similar reliability but differed in applicability: A random sampling observational studies of systematic reviews\/meta-analysis","volume":"14","author":"Zhang","year":"2021","journal-title":"J Evid Based Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2009.04.010","article-title":"Long-term results of concurrent radiotherapy and UFT in patients with locally advanced pancreatic cancer","volume":"92","author":"Bjerregaard","year":"2009","journal-title":"Radiotherapy Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1097\/01.coc.0000071462.12769.35","article-title":"Neoadjuvant chemoradiation with Tegafur in cancer of the pancreas -: Initial analysis of clinical tolerance and outcome","volume":"27","author":"Calvo","year":"2004","journal-title":"Am J Clin Oncology-Cancer Clin Trials"},{"key":"B25","doi-asserted-by":"crossref","DOI":"10.1016\/S0360-3016(00)00496-X","article-title":"A phase I study of combined UFT plus leucovorin and radiotherapy for pancreatic cancer","volume":"47","author":"Childs","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.7208","article-title":"miR-21 expression and clinical outcome in locally advanced pancreatic cancer: Exploratory analysis of the pancreatic cancer Erbitux, radiotherapy and UFT (PERU) trial","volume":"7","author":"Khan","year":"2016","journal-title":"Oncotarget"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2010.10.016","article-title":"Phase II trial of Uracil\/Tegafur plus leucovorin and celecoxib combined with radiotherapy in locally advanced pancreatic cancer","volume":"98","author":"Morak","year":"2011","journal-title":"Radiotherapy Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3892\/or.14.2.401","article-title":"Phase II study on low dose gemcitabine plus oral chemotherapy with uracil-tegafur and cyclophosphamide in combination with radiotherapy against recurrent and advanced pancreatic cancer","volume":"14","author":"Nio","year":"2005","journal-title":"Oncol Rep"},{"key":"B29","article-title":"Efficacy of whole body gamma-knife radiotherapy combined with thermochemotherapy on locally advanced pancreatic cancer. [Chinese","volume":"27","author":"Zhang","year":"2008","journal-title":"Ai Zheng = Aizheng = Chin J Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.10232","article-title":"Screening for pancreatic cancer: US preventive services task force reaffirmation recommendation statement","volume":"322","author":"Force","year":"2019","journal-title":"Jama"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2018.08.004","article-title":"Circadian variations in the pharmacokinetics of the oral anticancer agent tegafur-uracil (UFT) and its metabolites in rats","volume":"123","author":"Kobuchi","year":"2018","journal-title":"Eur J Pharm Sci"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpg.2016.07.002","article-title":"The rationale of combined radiotherapy and chemotherapy - Joint action of Castor and Pollux","volume":"30","author":"Brunner","year":"2016","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.05.017","article-title":"Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil\/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT\/LV","volume":"22","author":"Shirao","year":"2004","journal-title":"J Clin Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200746110-00003","article-title":"A clinical pharmacokinetic analysis of tegafur-uracil (UFT) plus leucovorin given in a new twice-daily oral administration schedule","volume":"46","author":"Etienne-Grimaldi","year":"2007","journal-title":"Clin Pharmacokinet"},{"key":"B35","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12885-015-1075-6","article-title":"Circadian variation in plasma 5-fluorouracil concentrations during a 24 hour constant-rate infusion","volume":"15","author":"Fleming","year":"2015","journal-title":"BMC Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1915790\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T04:29:48Z","timestamp":1788150588000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1915790\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":35,"alternative-id":["10.3389\/fonc.2026.1915790"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1915790","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]},"article-number":"1915790"}}